Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6256847rdf:typepubmed:Citationlld:pubmed
pubmed-article:6256847lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6256847lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:6256847lifeskim:mentionsumls-concept:C0341697lld:lifeskim
pubmed-article:6256847lifeskim:mentionsumls-concept:C0002435lld:lifeskim
pubmed-article:6256847lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:6256847lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:6256847pubmed:issue4lld:pubmed
pubmed-article:6256847pubmed:dateCreated1981-3-24lld:pubmed
pubmed-article:6256847pubmed:abstractText12 patients with severe renal insufficiency were treated for urinary tract infection with 400 mg of mecillinam intravenously every 6 h. High serum concentrations of mecillinam were found 6 h after the first morning dose on day 2 and day 5 of the treatment period (mean values 11.4 and 14.5 microgram/ml respectively), and a serum half-life of 334 min. In spite of reduced elimination of the drug, a nearly steady state was achieved within the first few days of treatment. Side effects were not observed.lld:pubmed
pubmed-article:6256847pubmed:languageenglld:pubmed
pubmed-article:6256847pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6256847pubmed:citationSubsetIMlld:pubmed
pubmed-article:6256847pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6256847pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6256847pubmed:statusMEDLINElld:pubmed
pubmed-article:6256847pubmed:issn0036-5548lld:pubmed
pubmed-article:6256847pubmed:authorpubmed-author:SvarvaP LPLlld:pubmed
pubmed-article:6256847pubmed:authorpubmed-author:Wessel-AasTTlld:pubmed
pubmed-article:6256847pubmed:issnTypePrintlld:pubmed
pubmed-article:6256847pubmed:volume12lld:pubmed
pubmed-article:6256847pubmed:ownerNLMlld:pubmed
pubmed-article:6256847pubmed:authorsCompleteYlld:pubmed
pubmed-article:6256847pubmed:pagination303-5lld:pubmed
pubmed-article:6256847pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:meshHeadingpubmed-meshheading:6256847-...lld:pubmed
pubmed-article:6256847pubmed:year1980lld:pubmed
pubmed-article:6256847pubmed:articleTitleSerum levels of mecillinam in patients with severely impaired renal function.lld:pubmed
pubmed-article:6256847pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6256847pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6256847lld:pubmed